In summary, our findings indicate that the combined inhibition of the JAK/STAT and mTOR pathways by novel more potent inhibitors can effectively inhibit cell signaling and reduce leukemia burden in CRFL2-re Ph-like B-ALL cell lines and PDX models. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.